MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

NEOG

9.6

+4.92%↑

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Gesloten

5.6 14.75

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.12

Max

5.8100000000000005

Belangrijke statistieken
By Trading Economics
Inkomsten	1.6M -12M
Verkoop	554K 18M
Winstmarge	-65.968
Werknemers	226
EBITDA	1.6M -9.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+13.04% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	27M 150M
Vorige openingsprijs	-9.15
Vorige sluitingsprijs	5.6

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 apr 2026, 23:36 UTC

Acquisities, Fusies, Overnames

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 apr 2026, 23:24 UTC

Populaire aandelen

Stocks to Watch: Gloo, Broadcom, GitLab

14 apr 2026, 22:42 UTC

Acquisities, Fusies, Overnames

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 apr 2026, 21:32 UTC

Belangrijke Marktbewegers

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 apr 2026, 23:54 UTC

Marktinformatie

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 apr 2026, 22:54 UTC

Winsten

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 apr 2026, 22:54 UTC

Winsten

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 apr 2026, 22:54 UTC

Winsten

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 apr 2026, 22:54 UTC

Winsten

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 apr 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 apr 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 apr 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 apr 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 apr 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 apr 2026, 22:14 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 apr 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 apr 2026, 22:12 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 apr 2026, 22:12 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 apr 2026, 22:10 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 apr 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

14 apr 2026, 20:33 UTC

Acquisities, Fusies, Overnames

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 20:32 UTC

Populaire aandelen

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 apr 2026, 19:59 UTC

Acquisities, Fusies, Overnames

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 19:38 UTC

Winsten

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 19:27 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 apr 2026, 19:21 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 apr 2026, 19:09 UTC

Acquisities, Fusies, Overnames

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 apr 2026, 18:30 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 apr 2026, 18:30 UTC

Marktinformatie

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

13.04% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.33 USD 13.04%

Hoogste 10 USD

Laagste 3.5 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.